| Project item | Indications | Research phase | Cooperation demands |
| BBS21008 | Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. | Pre-clinical, CMC developing; | Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.) |
Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μL stock solution per million cells (QC tested).
Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolgolimab | BCD-100 | Approved | Biocad | Forteca | Russian Federation | Melanoma | Biocad | 2020-04-01 | Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
| Dostarlimab | WBP-285; TSR-042; ANB-011 | Approved | Anaptysbio | JEMPERLI | United States | Solid tumours | Glaxosmithkline Llc | 2021-04-21 | Solid tumours; Ovarian Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Zimberelimab | AB-122; GLS-010; WBP-3055 | Approved | Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Apptec Co Ltd | Mainland China | Hodgkin Disease | Guangzhou Yuheng Biotechnology Co Ltd | 2021-08-25 | Multiple Myeloma; Adenocarcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Hodgkin Disease; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Ovarian Neoplasms | Details | |
| Penpulimab | AK-105 | Approved | Zhongshan Akeso Biopharma Co Ltd | 安尼可 | Mainland China | Hodgkin Disease | Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd | 2021-08-03 | Solid tumours; Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Camrelizumab | SHR-1210; INCSHR-1210; HR-301210 | Approved | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | AiRuiKa, 艾瑞卡, 艾立妥 | Mainland China | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2019-05-29 | Sarcoma; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Urologic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Respiratory Tract Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Breast Neoplasms; Lung Diseases; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Triple Negative Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic | Details |
| Toripalimab | SO-001; TAB-001; JS-001; JS-001sc | Approved | Suzhou Union Biopharm Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd | 拓益 | Mainland China | Carcinoma, Transitional Cell | Shanghai Junshi Biological Engineering Co Ltd | 2018-12-17 | Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Liposarcoma; Neuroendocrine Tumors; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Kidney Neoplasms | Details |
| Nivolumab | ONO-4538; ono-0123; BMS-936558; MDX-1106; BMS-936558-01 | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | 欧狄沃, Opdivo | EU | Esophageal Neoplasms | Bristol-Myers Squibb Pharma Eeig | 2014-07-04 | Diarrhea; Lung Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Peritoneal Neoplasms; Hepatitis C; Colorectal Neoplasms; Neuroblastoma; Brain Neoplasms; Hepatitis B; Esophageal Squamous Cell Carcinoma; Lymphoma, Mantle-Cell; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Sarcoma, Ewing; Microsatellite Instability; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Esophageal adenocarcinoma; Large intestine neoplasm; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Multiple Myeloma; Urogenital Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Glioma; Endometrial Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Chondrosarcoma; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Medulloblastoma; Skin Melanoma; Ependymoma; Irritable Bowel Syndrome; Hematologic Ne | Details |
| Tislelizumab | BGB-A317; VDT-482 | Approved | Beigene Ltd | 百泽安 | Mainland China | Carcinoma, Hepatocellular | Beigene (Shanghai) Biotechnology Co Ltd | 2019-12-26 | Lymphoma, Mantle-Cell; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, T-Cell; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Breast Neoplasms; Lymphoma, Follicular; Lymphoma, Extranodal NK-T-Cell; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone | Details |
| Sintilimab | IBI-308 | Approved | Innovent Biologics(Suzhou) Co Ltd | Tyvyt, 达伯舒 | Mainland China | Carcinoma, Hepatocellular | Innovent Biologics(Suzhou) Co Ltd | 2018-12-24 | Osteosarcoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Endometrial Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Lymphoma, Extranodal NK-T-Cell; Nasopharyngeal Carcinoma; Adenocarcinoma of Lung; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Hodgkin Disease; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| Pembrolizumab | SCH-900475; h409A11; MK-3475 | Approved | Merck & Co Inc | 可瑞达, Keytruda | Japan | Endometrial Neoplasms | Msd Kk | 2014-09-04 | Solid tumours; Head and Neck Neoplasms; Endocrine Gland Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Liver Neoplasms; Skin Melanoma; Leiomyosarcoma; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Merkel Cell; Anus Neoplasms; Bronchial Neoplasms; Carcinoid Tumor; Viremia; Rectal Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms, Glandular and Epithelial; Glioblastoma; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Neoplasms, Squamous Cell; Lymphoma, Large B-Cell, Diffuse; Salivary Gland Neoplasms; Nasopharyngeal Neoplasms; Adenocarcinoma of Lung; Inflammatory Breast Neoplasms; Neuroectodermal Tumors; Ganglioglioma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Microsatellite instability-high cancer; Neuroendocrine Tumors; Digestive System Neop | Details |
| Cemiplimab | REGN-2810; SAR-439684 | Approved | Regeneron Pharmaceuticals Inc | Libtayo | United States | Carcinoma, Non-Small-Cell Lung | Regeneron Pharmaceuticals Inc | 2018-09-28 | Diffuse Intrinsic Pontine Glioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Hepatitis B; Prostatic Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Skin Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Solid tumours | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
| Programmed cell death 1 antibody (Sun Yat-sen University) | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
| 9MW1111 | 9MW1111; 9MW-1111; 9-MW1111; 9-MW-1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
| EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) | Phase 2 Clinical | Xinqiao Hospital, Army Medical University | Squamous Cell Carcinoma of Head and Neck | Details | |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus | Autoimmune Diseases; Lymphoma, T-Cell | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Lymphoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Sarcoma | Details | |
| Izuralimab | XmAb-104; XmAb-23104 | Phase 1 Clinical | Xencor | Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
| RO-7121661 | RG-7769; RO-7121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| JS-201 | JS-201 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Neoplasms | Details |
| PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| LBL-015 | LBL-015 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Solid tumours | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Phase 2 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details | |
| MK-3475A | MK-3475A | Merck Sharp & Dohme Corp | Details | ||
| Vudalimab | XmAb-20717; XmAb-717 | Phase 2 Clinical | Xencor | Nasopharyngeal Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Endometrial Neoplasms; Colorectal Neoplasms; Astrocytoma; Vulvar Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Adnexal Diseases; Mesothelioma; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio | Autoimmune Diseases; Psoriasis | Details |
| PD-1 knockout engineered T cells (Cell Biotech) | Phase 1 Clinical | Cell Biotech | Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms | Details | |
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 1 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | Details | |
| W0180 | Phase 1 Clinical | Pierre Fabre Medicament | Solid tumours | Details | |
| SI-B003 | SI-B003 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| PE0105 | PE-0105 | Phase 1 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Neoplasms | Details |
| BAT-1308 | BAT-1308 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 2 Clinical | Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital | Esophageal Neoplasms | Details | |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| BCD-217 | BCD-217 | Phase 2 Clinical | Biocad | Melanoma | Details |
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
| 89Zr-N-sucDf-pembrolizumab | Phase 1 Clinical | Merck & Co Inc, Umcg The University Medical Center Groningen | Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
| CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
| LZM-009 | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
| QL1604 | QL1604; QL-1604 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms; Adenocarcinoma | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-0680 | AMP-514; MEDI-0680 | Phase 2 Clinical | Medimmune | Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell | Details |
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
| Sym-021 | Sym-021 | Phase 1 Clinical | Symphogen | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
| YBL-006 | YBL-006; YBL 006 | Phase 1 Clinical | Solid tumours | Details | |
| BA1104 | LY-01015; BA-1104 | Phase 1 Clinical | Luye Pharma Group Ltd | Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Stomach Neoplasms; Esophageal adenocarcinoma | Details | |
| T3011疱疹病毒（深圳市亦诺微医药） | MVR-T3011 | Phase 2 Clinical | Immvira Co Ltd | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Mesothelioma; Breast Neoplasms; Lymphoma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details |
| PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
| Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangsheng Tang Co Ltd, Xiamen University | Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details | |
| IMU-201 | IMU-201 | Phase 1 Clinical | Imugene | Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HerinCAR-PD1 | Phase 2 Clinical | Ningbo Cancer Hospital | Solid tumours | Details | |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
| Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) | Phase 1 Clinical | Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd | Bile Duct Neoplasms | Details | |
| STW204 | STW-204; AI025; AI-025 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Solid tumours; Neoplasms | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxi Weiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
| HPV E6-specific TCR-T cells | SIM-325; TC-E202 | Phase 1 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
| CMAB-819 | CMAB8-19 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Cetrelimab | JNJ-3283; JNJ-63723283 | Phase 3 Clinical | Johnson & Johnson | Neoplasms; Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
| GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| MW-11 | MW-11 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hodgkin Disease; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| MEDI-5752 | MEDI-5752 | Phase 1 Clinical | Medimmune Llc | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
| AZD-7789 | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Carcinoma, Non-Small-Cell Lung | Details |
| IBI-318(Innovent Biologics/Eli Lilly And Company) | LY-3434172; LY3434172; IBI-318 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Treprilimab | Clinical | Sun Yat-Sen University | Oropharyngeal Neoplasms | Details | |
| Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) | BAT-1306 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Stomach Neoplasms | Details |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin | Details |
| Pimivalimab | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AZD-2936 | AZD-2936 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung | Details |
| HX-009 | HX-009 | Phase 2 Clinical | Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| SSI-361 | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Neoplasms | Details |
| SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| QL-1706 | QL-1706; PSB-205 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms | Details |
| Tebotelimab | MGD-013; PD-1 X LAG-3 | Phase 3 Clinical | Macrogenics | Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Endometrial Neoplasms; Cholangiocarcinoma; Solid tumours; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms | Details |
| ZG-005 | ZG-005 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
| 609-A | 609-A | Phase 2 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Solid tumours; Sarcoma | Details |
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
| PH-762 | PH-762 | Phase 1 Clinical | Breast Neoplasms; Melanoma | Details | |
| Rulonilimab | F-520 | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours; Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms | Details |
| NIR-178 | PBF-509; NIR-178 | Phase 2 Clinical | Palobiofarma | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Lorigerlimab | MGD-019 | Phase 1 Clinical | Macrogenics | Skin Melanoma; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Sumgen) | SG-001; SYSA1802 | Phase 2 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nofazinlimab | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
| ABBV-1882 | ABBV-1882 | Phase 1 Clinical | Abbvie Inc | HIV Infections | Details |
| IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| IBI-319 | IBI-319 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
| Finotonlimab | SCT-I10A | Phase 3 Clinical | SinoCelltech Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours | Details |
| Zeluvalimab | AMG-404 | Phase 2 Clinical | Amgen Inc | Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Nivolumab/Relatlimab | BMS-936558/BMS-986016; BMS-986213 | Phase 3 Clinical | Bristol-Myers Squibb Company | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Melanoma | Details |
| Rosnilimab | ANB-030 | Phase 2 Clinical | Anaptysbio Inc | Alopecia Areata | Details |
| Budigalimab | ABBV-181 | Phase 2 Clinical | Abbvie Inc | HIV Infections; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CA-170 | AUPM-170; CA-170 | Phase 1 Clinical | Aurigene | Solid tumours | Details |
| AMG-256 | AMG-256 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| Spartalizumab(Novartis Pharma) | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Lymphoma; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Bone Marrow Diseases; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Chordoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Carcinoma, Hepatocellular; Persistent Fetal Circulation Syndrome; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid; Liver Neoplasms; Leukemia; Hematologic Diseases; Kidney Neoplasms; Preleukemia; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Thyroid Carcinoma, Anaplastic; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Neoplasm | Details |
| Ivonescimab | AK-112 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| Mavezelimab/Pembrolizumab | MK-4280A | Phase 3 Clinical | Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Peramprizumab | Phase 2 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
| LY-3462817 | LY-3462817 | Phase 2 Clinical | Eli Lilly And Company | Arthritis, Rheumatoid; Psoriasis | Details |
| RO-7247669 | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Liver Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Retifanlimab | INCMGA-0012; INCMGA-00012; MGA-012 | Phase 3 Clinical | Macrogenics | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Solid tumours | Details |
| Sasanlimab | PF-06801591; PF-6801591; RN-888 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details | |
| SHR-1901 | SHR-1901 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| Pembrolizumab biosimilar (biocad) | BCD-201 | Phase 1 Clinical | Biocad | Solid tumours | Details |
| Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
